Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H50F6N14O6.4ClH |
Molecular Weight | 1082.749 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.Cl.Cl.NC(=N)NCCCCC(=O)NC1=C(O[C@@H]2CCNC2)C(NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(NC(=O)CCCCNC(N)=N)=C4O[C@@H]5CCNC5)C(F)(F)F)=CC(=C1)C(F)(F)F
InChI
InChIKey=QTHBCQCKYVOFDR-PIJQHSLXSA-N
InChI=1S/C40H50F6N14O6.4ClH/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50;;;;/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54);4*1H/t23-,24-;;;;/m1..../s1
Brilacidin (formerly PMX-30063) is a polymer-based antibiotic and an investigational new drug, that was studied in human clinical trials, and represents a new class of antibiotics called host defense protein mimetics. Brilacidin is an antibiotic that works by disrupting bacterial cell membranes, mimicking defensins that play a role in innate immunity. Brilacidin has shown great efficacy in phase II clinical trials against acute Staphylococcus aureus skin and skin structure infections, comparable to that of the lipopeptidic drug daptomycin, which is currently used clinically to treat drug-resistant staph infections. Brilacidin also has potent broad-spectrum activity in vitro against several other Gram-positive and Gram-negative pathogenic bacteria, including several multidrug-resistant strains.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02324335
3 mg in 1 ml of Water for Injection, 3 times daily for 7 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CM3HYX69SK
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL2219413
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
100000175133
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
C142966
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
DBSALT002930
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
1224095-99-1
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
45275360
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
ZZ-17
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY | |||
|
DTXSID50153595
Created by
admin on Sat Dec 16 03:00:02 GMT 2023 , Edited by admin on Sat Dec 16 03:00:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD